Cosmo Pharmaceuticals S.p.A Stock Deutsche Boerse AG
Equities
IT0004167463
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- EUR | - |
|
Jun. 18 | Switzerland's Cosmo Pharmaceuticals Receives Drug Registration Certificate for Lumeblue in China | MT |
Jun. 03 | Cosmo Pharmaceuticals Swings to Loss in FY23; Revenue Down | MT |
Sales 2024 * | 249M 272M | Sales 2025 * | 220M 240M | Capitalization | 1.17B 1.27B |
---|---|---|---|---|---|
Net income 2024 * | 113M 123M | Net income 2025 * | 74M 80.7M | EV / Sales 2024 * | 4.07 x |
Net cash position 2024 * | 155M 169M | Net cash position 2025 * | 220M 240M | EV / Sales 2025 * | 4.32 x |
P/E ratio 2024 * |
9.58
x | P/E ratio 2025 * |
12.9
x | Employees | - |
Yield 2024 * |
2.4% | Yield 2025 * |
1.59% | Free-Float | 44.36% |
Latest transcript on Cosmo Pharmaceuticals S.p.A
Managers | Title | Age | Since |
---|---|---|---|
Niall Donnelly
DFI | Director of Finance/CFO | 52 | 16-05-31 |
Chairman | 61 | 05-12-31 | |
Chief Tech/Sci/R&D Officer | 54 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 69 | 96-12-31 | |
Director/Board Member | 69 | 12-03-31 | |
Chairman | 61 | 05-12-31 |
1st Jan change | Capi. | |
---|---|---|
+62.66% | 854B | |
+40.42% | 636B | |
-4.37% | 361B | |
+17.16% | 324B | |
+9.87% | 301B | |
+15.66% | 247B | |
+4.21% | 230B | |
+17.90% | 228B | |
+14.86% | 177B |